Senti Biosciences Holdings (SNTI) EPS (Basic) (2021 - 2025)

Senti Biosciences Holdings (SNTI) posted quarterly EPS (Basic) of -$5.22 for Q4 2025, down 655.29% quarter-over-quarter from -$0.69 in Q3 2025.

Senti Biosciences Holdings (SNTI) EPS (Basic) (2021 - 2025) Analysis & Trends

Senti Biosciences Holdings' EPS (Basic) history runs 5 years deep, the most recent figure standing at -$5.22 for Q4 2025.

In Q4 2025, EPS (Basic) changed N/A year-over-year to -$5.22; the TTM figure through Dec 2025 stood at -$7.31 (up 35.62% YoY), while the FY2025 annual figure was -$7.45, changed N/A from the prior year.
EPS (Basic) for Q4 2025 stood at -$5.22, down from -$0.69 in the prior quarter.
The five-year high for EPS (Basic) was $4.88 in Q3 2023, with the low at -$115.26 in Q4 2021.
The 5-year median for EPS (Basic) is -$2.45 (2024), against an average of -$11.03.
The sharpest annual moves came in 2022 and 2023: EPS (Basic) slumped 209924.29% in 2022, then soared 1006.3% in 2023.
Senti Biosciences Holdings' EPS (Basic) stood at -$115.26 in 2021, then jumped by 97.16% to -$3.27 in 2022, then surged by 99.81% to -$0.01 in 2023, then plunged by 99841.82% to -$6.31 in 2024, then gained by 17.23% to -$5.22 in 2025.
Business Quant data shows SNTI's EPS (Basic) at -$5.22 in Q4 2025, -$0.69 in Q3 2025, and -$0.56 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn	4.34
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn	12.62
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn	7.59
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn	-1.96
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn	2.12
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn	1.23
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn	-0.72
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	-0.06
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	0.18
10	Senti Biosciences Holdings	11.83 Mn	11.83 Mn	-	-0.46

Download Data